483 related articles for article (PubMed ID: 23900783)
1. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.
Karosiene E; Rasmussen M; Blicher T; Lund O; Buus S; Nielsen M
Immunogenetics; 2013 Oct; 65(10):711-24. PubMed ID: 23900783
[TBL] [Abstract][Full Text] [Related]
2. Peptide binding predictions for HLA DR, DP and DQ molecules.
Wang P; Sidney J; Kim Y; Sette A; Lund O; Nielsen M; Peters B
BMC Bioinformatics; 2010 Nov; 11():568. PubMed ID: 21092157
[TBL] [Abstract][Full Text] [Related]
3. TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules.
Zhang L; Chen Y; Wong HS; Zhou S; Mamitsuka H; Zhu S
PLoS One; 2012; 7(2):e30483. PubMed ID: 22383964
[TBL] [Abstract][Full Text] [Related]
4. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan.
Nielsen M; Lundegaard C; Blicher T; Peters B; Sette A; Justesen S; Buus S; Lund O
PLoS Comput Biol; 2008 Jul; 4(7):e1000107. PubMed ID: 18604266
[TBL] [Abstract][Full Text] [Related]
5. Improved methods for predicting peptide binding affinity to MHC class II molecules.
Jensen KK; Andreatta M; Marcatili P; Buus S; Greenbaum JA; Yan Z; Sette A; Peters B; Nielsen M
Immunology; 2018 Jul; 154(3):394-406. PubMed ID: 29315598
[TBL] [Abstract][Full Text] [Related]
6. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population.
McKinney DM; Southwood S; Hinz D; Oseroff C; Arlehamn CS; Schulten V; Taplitz R; Broide D; Hanekom WA; Scriba TJ; Wood R; Alam R; Peters B; Sidney J; Sette A
Immunogenetics; 2013 May; 65(5):357-70. PubMed ID: 23392739
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the structural basis and energetic landscape of susceptibility difference between HLA isotypes to allergic rhinitis.
Mao XL; Zhu F; Pan ZH; Wu GM; Zhu HY
Comput Biol Chem; 2016 Oct; 64():210-216. PubMed ID: 27433817
[TBL] [Abstract][Full Text] [Related]
8. MultiRTA: a simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes.
Bordner AJ; Mittelmann HD
BMC Bioinformatics; 2010 Sep; 11():482. PubMed ID: 20868497
[TBL] [Abstract][Full Text] [Related]
9. Towards universal structure-based prediction of class II MHC epitopes for diverse allotypes.
Bordner AJ
PLoS One; 2010 Dec; 5(12):e14383. PubMed ID: 21187956
[TBL] [Abstract][Full Text] [Related]
10. The Utility of Supertype Clustering in Prediction for Class II MHC-Peptide Binding.
Shen WJ; Zhang X; Zhang S; Liu C; Cui W
Molecules; 2018 Nov; 23(11):. PubMed ID: 30463372
[TBL] [Abstract][Full Text] [Related]
11. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification.
Andreatta M; Karosiene E; Rasmussen M; Stryhn A; Buus S; Nielsen M
Immunogenetics; 2015 Nov; 67(11-12):641-50. PubMed ID: 26416257
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of CD4
Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
Front Immunol; 2020; 11():602014. PubMed ID: 33658991
[TBL] [Abstract][Full Text] [Related]
13. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.
Nielsen M; Lundegaard C; Lund O
BMC Bioinformatics; 2007 Jul; 8():238. PubMed ID: 17608956
[TBL] [Abstract][Full Text] [Related]
14. HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.
van Lith M; McEwen-Smith RM; Benham AM
J Biol Chem; 2010 Dec; 285(52):40800-8. PubMed ID: 20959457
[TBL] [Abstract][Full Text] [Related]
15. Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens.
El-Awar N; Terasaki PI; Cai J; Deng CT; Ozawa M; Nguyen A; Lias M; Conger N
Clin Transpl; 2009; ():295-321. PubMed ID: 20524293
[TBL] [Abstract][Full Text] [Related]
16. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A.
Mollick JA; Cook RG; Rich RR
Science; 1989 May; 244(4906):817-20. PubMed ID: 2658055
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the expression of three different BoLA-class II molecules on the bovine BL-3 cell line: determination of a non-DR non-DQ gene product.
Ababou A; Goyeneche J; Davis WC; Lévy D
J Leukoc Biol; 1994 Aug; 56(2):182-6. PubMed ID: 7520928
[TBL] [Abstract][Full Text] [Related]
18. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA.
Jucaud V
J Immunol Res; 2017; 2017():2748614. PubMed ID: 28331856
[TBL] [Abstract][Full Text] [Related]
19. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
[TBL] [Abstract][Full Text] [Related]
20. First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry.
Duquesnoy RJ; Marrari M; Tambur AR; Mulder A; Sousa LC; da Silva AS; do Monte SJ
Hum Immunol; 2014 Nov; 75(11):1097-103. PubMed ID: 25305456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
